Episode 54
Biotech Hangout
00:00
Sedara Approves Candidemia Treatment
Sedara's approval of a new treatment for Candidemia has sent its stock down 25%. The company is not actually commercializing the product. And I think it's another unfortunate brick in the wall of lack of confidence in the commercial market for antibacterial and antifungals. But we really need more products for resistant bacterial infections and very difficult to treat fungal infections.
Transcript
Play full episode
